Table 2.

Demographic and baseline characteristics

	Women with established osteoporosisa
	Placebo n = 566	Risedronate n = 1090
Age, years
Mean ±s D	77 ± 5	77 ± 5
≥80 years, n (%)	122 (22)	250 (23)
Time since menopause, years, mean ± SD	31 ± 9	31 ± 9
Height, cm, mean ± SD	155.1 ± 7.2	154.6 ± 7.0
Weight, kg, mean ± SD	58.8 ± 10.6	58.1 ± 10.4

^aFemoral neck T-score NHANES III ≤ −2.5 and ≥ 1 prevalent vertebral fractures.

Abbreviation: SD, standard deviation.